Hongsik Jake Cho, a researcher at the University of Tennessee Health Science Center (UTHSC) in the US, is initiating a project to accelerate progress in stem cell treatment for post-traumatic osteoarthritis (PTOA).

UTHSC orthopaedic surgery and biomedical engineering associate professor Dr Cho has received a $1.56m rehabilitation research and development award from the US Department of Veterans Affairs. The award will support his study for four years.

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

Dr Cho will study a two-step method for improving the unhealthy environment in the arthritic knee joint.

The first step involves the use of nanosomes to deliver anti-inflammatory and antioxidant substances directly to the affected area to lower inflammation and counteract harmful oxidative stress effects.

In the second step, the longevity of transplanted stem cells is enhanced through a pre-transplantation antioxidant treatment.

This procedure further extends the timeframe of stem cells to exert their immune-suppressive functions and engage in cartilage repair.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

The pretreatment approach using the nanosome technique aims to improve stem cell viability.

Dr Cho will test this intervention in an animal model and the data collected will be used for potential future treatments in patients.

Dr Cho stated: “By studying this treatment strategy, we hope to develop a better understanding of how to improve the conditions in arthritic joints and increase the chances of successful stem cell therapy.

“This research is an important step in bringing new treatments to patients with PTOA.”

PTOA is a disabling condition that occurs after a single or repeated injury. Veterans in particular are at high risk of developing this condition and it is mostly observed in younger individuals.

Pharmaceutical Technology Excellence Awards - Nominations Closed

Nominations are now closed for the Pharmaceutical Technology Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact.

Excellence in Action
Awarded the 2025 Pharmaceutical Technology Excellence Award for Business Expansion in Integrated Manufacturing, Upperton Pharma Solutions is rapidly expanding its UK GMP and sterile manufacturing footprint. Find out how Upperton’s integrated CDMO model helps pharma companies move from early development to clinical and niche commercial supply with fewer handovers and faster timelines.

Discover the Impact